/GSK
GSK plc
GSK • NYSEGSK • NYSE • Healthcare
$56.83-0.42%-0.24
$56.83-0.42%(-0.24)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
5Bearish
Risk
100Low Risk
Momentum
91Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
72.5%▲1.4pp
Revenue after COGS
Operating
21.9%▲9.1pp
After operating expenses
Net
17.5%▲9.3pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
13.2
Price vs earnings
EV/EBITDA
7.6
Enterprise value
FCF Yield
7.9%
Cash generation
Earnings Yield
7.6%
Inverse of P/E
Capital Efficiency
19
GoAI Quality ScoreStrong
ROEReturn on Equity
34.2%Strong
ROAReturn on Assets
9.2%Strong
ROICReturn on Invested Capital
14.0%Strong
Financial Health
Current RatioWeak
0.82
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
1.23x
Debt repayment capacity (<3x)
Income QualityStrong
1.28
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $31.95B | $31.38B | $30.33B | $29.32B | $24.70B |
| Gross Profit | $23.18B | $22.33B | $21.76B | $19.77B | $16.53B |
| Gross Margin | 72.5% | 71.2% | 71.8% | 67.4% | 66.9% |
| Operating Income | $7.01B | $4.02B | $6.75B | $6.43B | $4.36B |
| Net Income | $5.59B | $2.58B | $4.93B | $14.96B | $4.38B |
| Net Margin | 17.5% | 8.2% | 16.2% | 51.0% | 17.8% |
| EPS | $2.76 | $1.26 | $2.44 | $2.44 | $2.74 |
Average Price Target
$53.00▼ 6.7% Downside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for GSK plc, the average price target is $53.00, with a high forecast of $53.00 and a low forecast of $53.00. The average price target represents a 6.7% decrease from the current price of $56.83.
Highest
$53.00
Average
$53.00
Lowest
$53.00
Rating Distribution
Strong Buy
0
0%
Buy
9
31%
Hold
16
55%
Sell
4
14%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays▼ Downgrade
Equal Weight→Underweight
2026-01-06Jefferies▼ Downgrade
Buy→Hold
2024-11-12Guggenheim▼ Downgrade
Buy→Neutral
2024-10-31UBS▼ Downgrade
Buy→Neutral
2024-07-08Jefferies● Maintain
Buy
2024-07-02Guggenheim▲ Upgrade
Neutral→Buy
2024-03-04Jefferies▲ Upgrade
Hold→Buy
2024-01-03DZ Bank▼ Downgrade
Buy→Hold
2022-02-11Barclays▲ Upgrade
Underweight→Equal Weight
2021-11-05SVB Leerink▼ Downgrade
Outperform→Market Perform
2021-03-23Earnings History & Surprises
BEAT RATE
94%
Last 18 quarters
AVG SURPRISE
+14.1%
EPS vs Estimate
BEATS / MISSES
17/1
Last 18 quarters
LATEST EPS
$0.68
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+6.3%
$0.68 vs $0.64
Q4 '25
+17.5%
$1.48 vs $1.26
Q3 '25
No data
Q2 '25
+4.6%
$1.13 vs $1.08
Q1 '25
+34.1%
$0.59 vs $0.44
Q4 '24
+9.5%
$1.27 vs $1.16
Q3 '24
+9.0%
$1.09 vs $1.00
Q1 '24
-5.3%
$0.72 vs $0.76
Q4 '23
+15.6%
$1.26 vs $1.09
Q3 '23
+11.5%
$0.97 vs $0.87
Q2 '23
+9.8%
$0.90 vs $0.82
Q1 '23
+8.5%
$0.64 vs $0.59
No investor questions available.
Latest News
No news available